Mission BioCapital

https://lnkd.in/eE4-YVnq

We’re excited to announce a $100 million Series C financing to advance our pipeline of selective ion channel modulators as non-opioid treatments for pain and sensory hyperexcitability disorders. Our lead program targets NaV1.8, a promising approach for meaningful analgesia with a reduced risk of abuse. We are also excited to explore the potential of sodium channels and other genetically and clinically validated targets to treat pain and sensory hyperexcitability disorders. Thank you to our investors: Novo Holdings for leading the round, and OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital Inc., and our existing investors for participating. Read the press release here: https://lnkd.in/gSFhUNc9 We also launched a new website! Learn more about how we're "owning the action potential" to deliver innovative therapies: https://lnkd.in/gWFt3pQk #nonopioidtherapies #painmanagement #pain #drugdiscovery #ionchannels #biotech #bayarea #financing #venturecapital

https://lnkd.in/gjECjHPT

We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and other neurodegenerative diseases and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. EKZ-102 is a highly selective, uniquely CNS-penetrant HDAC6 inhibitor with strong potential to be a first-in-class, disease-modifying therapy for ALS and other indications. Read the PR here: https://lnkd.in/eYSJcTBp

We’re thrilled to announce a $161 million Series B financing and the advancement to Phase 2 clinical studies for our lead candidate, NVG-2089! Our lead program, NVG-2089 aims to address high unmet needs for new non-immunosuppressive, efficacious therapies in autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP) and other indications. Thank you to our investors—Sanofi Ventures, Blue Owl Healthcare Opportunities, Norwest Venture Partners, B Capital , Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, funds managed by abrdn Inc., Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital—for supporting our mission to deliver innovative, non-immunosuppressive therapies for autoimmune diseases. Learn more about this milestone and our progress: https://lnkd.in/gxhqHG_v #inflammation #autoimmunedisease #proteintherapeutics #immunefunction #biotech #bayarea #financing #venturecapital

We’re excited to officially launch Jupiter Bioventures, a pioneering biotechnology venture foundry building bold, science-driven therapeutics companies. Co-Founders Nathaniel David, PhD, and Norman Sharpless, MD, bring decades of industry experience to drive a scalable foundry model, advancing #biotech innovation in #cancer and other areas in which insights from cancer biology provide insight. With $70 million raised from returning investors Mission BioCapital and Mayo Clinic alongside #lifescience investors Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, LLC, Fox Ventures, The Brent and Julie Callinicos Trust and Vault Fund, Jupiter will found, launch, and operate multiple therapeutics companies. https://lnkd.in/eaUJsaE8 Stay tuned as we pursue breakthrough science to deliver #innovation in life sciences.

We’re pleased to share that we’ve secured $28.4 million in an oversubscribed Series A financing round, co-led by Mission BioCapital and 4BIO Capital. This milestone brings our total funding to over $51 million and will help us accelerate the Phase 2 development of MB-105, our lead CAR-T therapy candidate for T-cell lymphoma – a type of cancer with a poor prognosis and limited treatment options.   Launching our Series A with a Phase 2 ready asset is something we're proud of and we are determined to push forward to provide new hope for patients with cancer who have few treatment options. We’re grateful to our new and existing investors for their confidence in our mission to transform the treatment landscape for challenging cancers!   https://lnkd.in/gySMtkWc #CellTherapy #Oncology #CancerResearch #SeriesA #CART #BiotechInnovation KdT Ventures TMC Venture Fund Portal Innovations, LLC Cancer Focus Fund Small Ventures USA LLC Alexandria Real Estate Equities, Inc. Modi Ventures Joe Mansueto Nancy Chang Stefan Wildt Cassidy Blundell Owen Smith Cancer Prevention and Research Institute of Texas

We are thrilled to announce that the official Grand Opening Celebration of BioLabs New Haven is just around the corner—less than three weeks away! 🗓️ Wednesday, September 25th. Join us as we welcome you into our new space at 101 College Street in New Haven. It’s going to be a fantastic event with special remarks from Mayor Justin Elicker and BioLabs CEO Johannes Fruehauf. We would love for you to be part of this milestone moment. Don’t miss out on celebrating with us and connecting with New Haven's vibrant life science community. #GrandOpening #NewHaven #Networking #Innovation #LifeScience #Biotech #Community https://lu.ma/pvwrksew

Thank you Johnson & Johnson Innovation and Mission BioCapital for cohosting a lovely VC University Life Science Scholars dinner with us in Boston this week! We convened an impressive group of alumni to network with and learn from VC leaders about building a VC career.